Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026628 | 0.86 | USP2 (0.41) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2828216 | 0.82 | NR1H2 (0.39) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2821808 | 0.81 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2726581 | 0.79 | USP2 (0.41) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL15251321 | 0.79 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2822607 | 0.79 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2826407 | 0.78 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2825447 | 0.77 | NR1H2 (0.35) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2826710 | 0.77 | NR1H2 (0.35) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT | |
| SCHEMBL2825450 | 0.77 | NR1H2 (0.35) | USP2SMN1; SMN2NR1H2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | USP2 2507/4885SMN1; SMN2 4001/4885CCR2 2408/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | USP2 4046/4885SMN1; SMN2 3604/4885CCR2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.